A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: Results of the GETUG S99 multicenter prospective study

European Urology

Volumn 65, Issue 2, 2014, Pages 381-386

  Fizazi, Karim ^a   Delva, Rémi ^b   Caty, Armelle ^c   Chevreau, Christine ^d   Kerbrat, Pierre ^e   Rolland, Frederic ^f   Priou, Frank ^g   Geoffrois, Lionnel ^h   Rixe, Olivier ⁱ   Beuzeboc, Philippe ^j   Malhaire, Jean Pierre ^k   Culine, Stephane ^l   Aubelle, Marie Stephanie ^a   Laplanche, Agnes ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE PAUL PAPIN   (France)

^c Ramsay Santé   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e CENTRE EUGÈNE MARQUIS   (France)

^f CENTRE RENÉ GAUDUCHEAU   (France)

^g Hôpital Les Oudairies   (France)

^h CENTRE ALEXIS VAUTRIN   (France)

ⁱ MEDICAL COLLEGE OF GEORGIA   (United States)

^j INSTITUT CURIE   (France)

^k CHU MORVAN   (France)

^l SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Chemotherapy; Prognostic factors; Seminoma

Indexed keywords

CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SEMINOMA; SEPTIC SHOCK; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; YOUNG ADULT;

CHEMOTHERAPY; PROGNOSTIC FACTORS; SEMINOMA;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FRANCE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SEMINOMA; TESTICULAR NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891824431     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.09.004     Document Type: Article

References (29)

1. J. Beyer, P. Albers, and R. Altena et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer Ann Oncol 24 2013 878 888
2. A. Jemal, R. Siegel, and J. Xu et al. Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
3. J. Domont, C. Massard, and A. Patrikidou et al. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma Urol Oncol 31 2013 697 705
4. K. Fizazi, S. Culine, and J.P. Droz et al. Initial management of primary mediastinal seminoma: radiotherapy or cisplatin-based chemotherapy? Eur J Cancer 34 1998 347 352
5. K. Fizazi, S. Culine, and J.P. Droz et al. Primary mediastinal non-seminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy J Clin Oncol 16 1998 725 732
6. C. Bokemeyer, C. Kollmannsberger, and S. Stenning et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials Br J Cancer 91 2004 683 687
7. D. Gholam, K. Fizazi, and M.J. Terrier-Lacombe et al. Advanced seminoma: treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients Cancer 98 2003 745 752
8. P.J. Mencel, R.J. Motzer, and M. Mazumdar et al. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients J Clin Oncol 12 1994 120 126
9. J.A. Arranz Arija, X. Garcia del Muro, and J. Guma et al. E400P in advanced seminoma of good prognosis according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience Ann Oncol 12 2001 487 491
10. P. Albers, W. Albrecht, and F. Algaba et al. EAU guidelines on testicular cancer: 2011 update Eur Urol 60 2011 304 319
11. 18fluoro- deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial Ann Oncol 23 2012 59 64
12. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers J Clin Oncol 15 1997 594 603
13. S.D. Fossa, R.T.D. Oliver, and S.P. Stenning et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy Eur J Cancer 33 1997 1380 1387
14. S. Culine, L. Abs, and M.J. Terrier-Lacombe et al. Cisplatin-based chemotherapy in advanced seminoma: the Institut Gustave Roussy experience Eur J Cancer 34 1998 353 358
15. S.D. Fossa, J.P. Droz, and G. Stoter et al. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874 Br J Cancer 71 1995 619 624
16. F. Farhat, S. Culine, and C. Théodore et al. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients. The Institut Gustave Roussy experience Cancer 77 1996 1193 1197
17. K. Miller, P.J. Loehrer, and R. Gonin et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma J Clin Oncol 15 1997 1427 1431
18. M. De Santis, A. Becherer, and C. Bokemeyer et al. 2-18fluoro-deoxy-D- glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial J Clin Oncol 22 2004 1034 1039
19. A. Horwich, R.T. Oliver, and P.M. Wilkinson et al. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party Br J Cancer 83 2000 1623 1629
20. R. de Wit, I. Skoneczna, and G. Daugaard et al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983 J Clin Oncol 30 2012 792 799
21. T. Tandstad, R. Smaaland, and A. Solberg et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian testicular cancer study group J Clin Oncol 29 2011 719 725
22. K. Fizazi, I. Chen, and C.J. Logothetis Germ cell tumor survivors: the price for cure Ann Oncol 13 2002 187 189
23. S. Culine, P. Kerbrat, A. Kramar Genito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP) Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP) Ann Oncol 18 2007 917 924
24. C.R. Nichols, P.J. Catalano, and E.D. Crawford et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study J Clin Oncol 16 1998 1287 1293
25. S. Hinton, P.J. Catalano, and L.H. Einhorn et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial Cancer 97 2003 1869 1875
26. M. Wagner, J. Bellmunt, and C. Boutros et al. False positive 18fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses Clin Genitourin Cancer 11 2013 66 69
27. C. Thibault, Y. Loriot, and D. Barrios Gonzales et al. Relapses in metastatic germ-cell tumors and relationship to international guidelines compliance: a study from the Institut Gustave Roussy [abstract 323] J Clin Oncol 30 Suppl 5 2012
28. J.L. Passos-Coelho, M. Castro Ribeiro, and E. Santos et al. Suboptimal survival of male germ-cell tumors in southern Portugal - a population-based retrospective study for cases diagnosed in 1999 and 2000 Ann Oncol 22 2011 1215 1220
29. C.R. Nichols, B. Roth, and C. Kollmannsberger Classical clinical trial design in testicular cancer: time to move on J Clin Oncol 30 2012 769 771